Clinical Policy: Sofosbuvir/Velpatasvir (Epclusa)

Reference Number: GA.PMN.06
Effective Date: 12/16
Last Review Date: 7/2021
Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Sofosbuvir/Velpatasvir (Epclusa®/™) is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor.

FDA Approved Indication(s)
Epclusa is indicated for the treatment of adult and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection:
- Without cirrhosis or with compensated cirrhosis
- With decompensated cirrhosis for use in combination with ribavirin (RBV)

Policy/Criteria
It is the policy of health plans affiliated with Centene Corporation® that Epclusa is medically necessary when the following criteria are met:

I. Initial Approval Criteria
** Provider must submit documentation (including office chart notes and lab results) supporting that member has met all approval criteria **

A. Chronic Hepatitis C Infection (must meet all):
1. Diagnosis of chronic hepatitis C virus (HCV) infection as evidenced by detectable HCV ribonucleic acid (RNA) levels in the last 6 months;
2. Age ≥ 6 years or weight ≥ 17 kg;
3. Member must use authorized generic version of Epclusa, unless contraindicated or clinically significant adverse effects are experienced;
4. Confirmed HCV genotype is 1, 2, 3, 4, 5 or 6;
   *Chart note documentation and copies of labs results are required
5. Documentation of the treatment status of the patient (treatment-naïve or treatment-experienced);
6. Documentation of cirrhosis status of the patient (no cirrhosis, compensated cirrhosis, or decompensated cirrhosis);
7. Life expectancy ≥ 12 months with HCV treatment;
8. Prescribed regimen is consistent with an FDA or AASLD-IDSA recommended regimen (see Section III Dosage and Administration for reference);
9. Member is hepatitis B virus (HBV) negative, or if positive, documentation that concurrent HBV infection is being treated (e.g., tenofovir alafenamide, adefovir,
entecavir), unless contraindicated or clinically significant adverse effects are experienced (see Appendix B);

10. If prescribed with ribavirin, member has none of the following contraindications:
   a. Pregnancy or possibility of pregnancy - member or partner;
   b. Hypersensitivity to ribavirin;
   c. Coadministration with didanosine;
   d. Significant/unstable cardiac disease;
   e. Hemoglobinopathy (e.g., thalassemia major, sickle cell anemia);
      a. Hemoglobin < 8.5 g/dL.

11. Dose does not exceed one of the following (a or b):
   a. Adult and pediatric members with body weight ≥ 30 kg: sofosbuvir/velpatasvir
      400 mg/100 mg (1 tablet) per day;
   b. Pediatric members with body weight 17 to 29 kg: sofosbuvir/velpatasvir 200
      mg/50 mg (1 tablet) per day.

   **Approval duration: up to a total of 24 weeks**
   *(Approved duration should be consistent with a regimen in Section III Dosage and Administration)*

B. **Other diagnoses/indications:** Refer to CP.PMN.53 – No Coverage Criteria/Off-Label
   Use Policy if diagnosis is NOT specifically listed under section I.

II. **Appendices/General Information**

   **Appendix A: Abbreviation/Acronym Key**

   AASLD: American Association for the Study of Liver Diseases
   APRI: AST to platelet ratio
   CTP: Child Turcotte Pugh
   CrCl: creatinine clearance
   FDA: Food and Drug Administration
   FIB-4: Fibrosis-4 index
   HCC: hepatocellular carcinoma
   HCV: hepatitis C virus
   IDS A: Infectious Diseases Society of America
   MRE: magnetic resonance elastography
   NS3/4A, NS5A/B: nonstructural protein
   Peg-IFN: pegylated interferon
   PI: protease inhibitor
   RBV: ribavirin
   RNA: ribonucleic acid
Appendix B: Contraindications

- Epclusa and RBV combination regimen is contraindicated in patients for whom RBV is contraindicated. Refer to the RBV prescribing information for a list of contraindications for RBV.
- Box warning (s): risk of hepatitis B virus reactivation in patients co-infected with HCV and HBV

Appendix C: Direct-Acting Antivirals for Treatment of HCV Infection

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Drug Class</th>
<th>NS5A Inhibitor</th>
<th>Nucleotide Analog NS5B Polymerase Inhibitor</th>
<th>Non-Nucleoside NS5B Palm Polymerase Inhibitor</th>
<th>NS3/4A Protease Inhibitor (PI)**</th>
<th>CYP3A Inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daklinza</td>
<td>Daclatasvir</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epclusa*</td>
<td>Velpatasvir</td>
<td>Sofosbuvir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harvoni*</td>
<td>Ledipasvir</td>
<td>Sofosbuvir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mavyret*</td>
<td>Pibrentasvir</td>
<td></td>
<td></td>
<td></td>
<td>Glecaprevir</td>
<td></td>
</tr>
<tr>
<td>Sovaldi</td>
<td></td>
<td>Sofosbuvir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viekira*/PAK*</td>
<td>Ombitasvir</td>
<td>Dasabuvir</td>
<td>Paritaprevir</td>
<td>Ritonavir</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vosevi*</td>
<td>Velpatasvir</td>
<td>Sofosbuvir</td>
<td></td>
<td></td>
<td>Voxilaprevir</td>
<td></td>
</tr>
<tr>
<td>Zepatier*</td>
<td>Elbasvir</td>
<td></td>
<td></td>
<td></td>
<td>Grazoprevir</td>
<td></td>
</tr>
</tbody>
</table>

*Combination drugs

Appendix D: General Information

- Hepatitis B Virus (HBV) Reactivation is a black box warning for all direct-acting antiviral drugs for the treatment of HCV. HBV reactivation has been reported when treating HCV for patients co-infected with HBV, leading to fulminant hepatitis, hepatic failure, and death, in some cases. Patients should be monitored for HBV reactivation and hepatitis flare during HCV treatment and post-treatment follow-up, with treatment of HBV infection as clinically indicated.
### III. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype 1-6: Without cirrhosis or with compensated cirrhosis, treatment-naïve or treatment-experienced* patient</td>
<td>One tablet PO QD for 12 weeks</td>
<td>One tablet (Adult/Peds ≥ 30 kg: sofosbuvir 400 mg /velpatasvir 100 mg; Peds 17 to 29 kg: sofosbuvir 200 mg /velpatasvir 50 mg) per day</td>
<td>FDA-approved labeling</td>
</tr>
<tr>
<td>Genotype 1-6: With decompensated cirrhosis, treatment-naïve or treatment-experienced* patient</td>
<td>One tablet PO QD with weight-based RBV for 12 weeks (RBV-ineligible patient may use: one tablet PO QD for 24 weeks)†</td>
<td>One tablet (Adult/Peds ≥ 30 kg: sofosbuvir 400 mg /velpatasvir 100 mg; Peds 17 to 29 kg: sofosbuvir 200 mg /velpatasvir 50 mg) per day</td>
<td>FDA-approved labeling</td>
</tr>
<tr>
<td>Genotype 1-6: Treatment-naïve and treatment-experienced patients, post-liver transplant with compensated cirrhosis or without cirrhosis</td>
<td>One tablet PO QD for 12 weeks</td>
<td>One tablet (sofosbuvir 400mg /velpatasvir 100 mg) per day</td>
<td>FDA-approved labeling</td>
</tr>
<tr>
<td>Genotype 1-6: With decompensated cirrhosis in whom prior sofosbuvir- or NS5A inhibitor-based treatment failed</td>
<td>One tablet PO QD with weight-based RBV for 24 weeks†</td>
<td>One tablet (sofosbuvir 400mg /velpatasvir 100 mg) per day</td>
<td>AASLD-IDSA (updated March 2021)</td>
</tr>
<tr>
<td>Genotype 1-6: Treatment-naïve and treatment-experienced patients, post-liver transplant with decompensated cirrhosis</td>
<td>One tablet PO QD with RBV (starting at 600 mg and increased as tolerated) for 12 weeks (treatment naïve) or 24 weeks (treatment experienced)†</td>
<td>One tablet (sofosbuvir 400mg /velpatasvir 100 mg) per day</td>
<td>AASLD-IDSA (updated March 2021)</td>
</tr>
<tr>
<td>Genotype 3 with NS5A Y93H polymorphism: Treatment-naïve with compensated cirrhosis or treatment-experienced* without cirrhosis patient</td>
<td>One tablet PO QD with weight-based RBV for 12 weeks†</td>
<td>One tablet (sofosbuvir 400mg /velpatasvir 100 mg) per day</td>
<td>AASLD-IDSA (updated March 2021)</td>
</tr>
</tbody>
</table>
AASLD/IDSA treatment guidelines for chronic hepatitis C infection are updated at irregular intervals; refer to the most updated AASLD/IDSA guideline for most accurate treatment regimen.

*Treatment-experienced refers to previous treatment with NS3 protease inhibitor (telaprevir, boceprevir, or simeprevir) and/or peginterferon/RBV unless otherwise stated

+ Off-label, AASLD-IDSA guideline-supported dosing regimen

IV. Product Availability

Tablet: sofosbuvir 400mg with velpatasvir 100mg, sofosbuvir 200mg with velpatasvir 50mg

V. References


Reviews, Revisions, and Approvals

| New policy created, split from CP.PHAR.17 Hepatitis C Therapies policy. HCV RNA levels over six-month period added to confirm infection is chronic. Life expectancy “≥12 months if HCC and awaiting transplant” is modified to indicate “≥12 months with HCV therapy.” Methods to diagnose fibrosis/cirrhosis are modified to require a liver biopsy or a combination of one serologic and one radiologic test. Serologic and radiologic tests are updated and correlated with METAVIR per Appendix C. Dosing regimens are presented in Appendix. Criteria is added requiring a verification of HCV RNA status at 4 weeks (and again at 6 weeks if present at 4) accordingly, the initial approval period is shortened to 8 weeks. | 07/16 | 07/16 |
| Edited policy so congruent with the other HCV policies as follows: Testing criteria reorganized by cirrhosis status consistent with the regimen tables; HCC population broadened to incorporate those amenable to curative measures (resection, ablation, transplant). Fibrosure test that meets F3 requirement changed to ≥ 0.59. Criteria added excluding post-liver transplantation unless regimens specifically designate. Preferencing language edited for clarity. Removed creatinine clearance restriction. Under continuing approval, presence of HCV RNA is edited to remove specific timing of testing. Appendix B edited for clarity; Appendix C added. Appendix D – genotype “1” is footnoted to clarify possible subtypes. | 08/16 | 09/16 |
### Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>Plan Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Includes HCC” is removed from the decompensated cirrhosis. “Daily” is removed from the “recommended regimen” column; presentation of other data is abbreviated/short-handed.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Removed criteria regarding medication prescribed by a specialist</td>
<td>9/16</td>
<td>9/2016</td>
</tr>
<tr>
<td>Remove criteria regarding having HCC or advanced liver disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Removed criteria regarding medication adherence program</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Removed criteria regarding sobriety from alcohol/illicit drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Added availability of full course of therapy as initial therapy consistent with appendix recommendation for initial criteria</td>
<td>4/17</td>
<td>4/17</td>
</tr>
<tr>
<td>Removed continuation criteria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Added preferencing information requiring Mavyret for FDA-approved indications. Added information requiring Hep B screening for all patients prior to treatment to ensure that proper risk reduction measures are taken.</td>
<td>9/17</td>
<td>9/17</td>
</tr>
<tr>
<td>Annual review. No changes made.</td>
<td>3/18</td>
<td>3/18</td>
</tr>
<tr>
<td>Changed current Georgia policy templates to corporate standard templates for drug coverage criteria to meet corporate compliance. Changes/revisions included; new formatting, font size, use of standard policy language for each section of policy, and rearranged order of certain steps in criteria and sections. Added new preferred treatment tables that includes dosage and frequency based on genotype for Mavyret. Removed background sections. Updated general information and contraindication section to be consistent with corporate HCV policies.</td>
<td>2/21/19</td>
<td>2/19</td>
</tr>
<tr>
<td>Annual review. In the initial approval criteria, changed RNA detectable period from “over a 6 month period” to “in the last 6 months” for infection diagnosis.</td>
<td>10/19</td>
<td>10/19</td>
</tr>
<tr>
<td>Added preferencing for AG Epclusa; Removed redirection to Mavyret based on contraindications criteria and all other information relative to Mavyret. Removed Appendix C for Metavir scoring. Updated order of all other Appendices. Updated references.</td>
<td>4/2020</td>
<td>4/2020</td>
</tr>
<tr>
<td>Added pediatric indication and dosing. References reviewed and updated.</td>
<td>7/2020</td>
<td>7/2020</td>
</tr>
<tr>
<td>Annual review. Added hepatitis B box warning to Appendix B Contraindications. Added Mayvret and Vosevi to Appendix D-Direct Acting Antivirals for Treatment of HCV infection and removed Olysio, Technivie, and Viekira XR as these were previously removed from the market. Updated Dosage and Administration table to include pediatric dosing when applicable, FDA-labeled dosing for post-liver transplant setting, references and grammatical updates. Added an additional tablet strength under product availability. Changed Centene Logo to PSHP Logo. References reviewed and updated.</td>
<td>4/2021</td>
<td>4/2021</td>
</tr>
<tr>
<td>Revised medical justification language for not using authorized generic version of Epclusa to “must use” language; updated Section III table with AASLD recommended regimens; references reviewed and updated.</td>
<td>7/2021</td>
<td>7/2021</td>
</tr>
</tbody>
</table>
Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed
herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:** For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.